

## Cobalamin/Propionate/Homocysteine Metabolism Related Disorders Panel

Disorders of cobalamin (vitamin B<sub>12</sub>)/propionate/homocysteine metabolism result from defects in the vitamin B<sub>12</sub> metabolic pathway. Age of disease onset ranges from the perinatal period to adulthood. Multiple organ systems are affected. Molecular testing is used to confirm suspected cobalamin/propionate/homocysteine metabolism-related disorder in individuals with clinical symptoms and/or biochemical findings.

### DISEASE OVERVIEW

#### Findings

- Cardiovascular
- Gastrointestinal
- Hematological
- Immunological
- Neurological
- Neuromuscular/skeletal
- Ocular
- Renal
- Respiratory
- Dysmorphic features
- Failure to thrive
- Metabolic decompensation

#### Etiology

- Defects of absorption, transport, and intracellular metabolism of cobalamin/propionate/homocysteine lead to accumulation of methylmalonic acid, methionine, and/or homocysteine in blood and urine.
- Elevated propionylcarnitine level and/or propionyl/acetylcarnitine ratio are usually detected in plasma, and increased methylmalonic acid is detected in blood, despite normal or elevated vitamin B<sub>12</sub> levels.

#### Prevalence

- Methylmalonic aciduria from all causes – 1/48,000-61,000 in North America
- Isolated methylmalonic acidemia – 1/50,000-100,000
- Combined malonic/methylmalonic aciduria – ~1/30,000
- Methylmalonic aciduria, vitamin B<sub>12</sub>-responsive, cblA type – 1/50,000-100,000
- Methylmalonic aciduria, vitamin B<sub>12</sub>-responsive, cblB type – 1/50,000-100,000
- Methylmalonic aciduria and homocystinuria, cblC type – up to 1/67,000
- Methylmalonic aciduria, and homocystinuria, cblD type – 1/50,000-100,000
- Methylmalonic aciduria, mut (0) type – 1/50,000-100,000
- Methylmalonyl-CoA epimerase deficiency – 1/50,000-100,000
- Homocystinuria due to cystathionine beta-synthase deficiency – 1/1,800 in Qatar; 1/6,400 in Norway; 1/17,800 in Germany
- Methionine adenosyltransferase deficiency – 1/22,000 in Spain; 1/26,000 in Portugal
- Homocystinuria, B<sub>6</sub>-responsive and nonresponsive types, combined – 1/58,000-1,000,000
- Propionic acidemia – 1/50,000-100,000; 1/1,000-2,000 in Inuit in Greenland; 1/5,000 in Saudi Arabia
- Rare for other disorders included in the panel

### TESTS TO CONSIDER

[Cobalamin/Propionate/Homocysteine Metabolism Related Disorders Panel, Sequencing and Deletion/Duplication 2011157](#)

Method: Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray

Confirm suspected cobalamin (vitamin B<sub>12</sub>)/propionate/homocysteine metabolism-related disorder in individuals with clinical symptoms and/or biochemical findings. Should not be ordered to assess vitamin B<sub>12</sub> level.

For tests to consider before ordering genetic testing, see [Related Tests](#).

## Inheritance

Autosomal recessive for all genes tested, except for *HCFC1* (X-linked) and *MAT1A* (autosomal dominant or autosomal recessive)

## Genotype-Phenotype Correlation

- Variants in multiple genes cause overlapping and highly variable phenotypes.
- Other genetic and/or biochemical/dietary factors may influence severity of clinical phenotype.
- Clinical features and age of onset are highly variable.

## TEST DESCRIPTION

See [Genes Tested](#) table for genes included in the panel.

## Clinical Sensitivity

Variable, dependent on condition

## Limitations

- A negative result does not exclude a heritable form of cobalamin metabolism disorders.
- Diagnostic errors can occur due to rare sequence variations.
- Interpretation of this test result may be impacted if the individual has had an allogeneic stem cell transplantation.
- The following will not be evaluated:
  - Variants outside the coding regions and intron-exon boundaries of the targeted genes
  - Regulatory region variants and deep intronic variants
  - Breakpoints of large deletions/duplications
  - Deletions/duplications in the *ADK*, *AHCY*, and *GNMT* genes
  - Non-coding transcripts
- The following may not be detected:
  - Deletions/duplications/insertions of any size by massively parallel sequencing
  - Deletions/duplications less than 1 kb in the targeted genes by array
  - Some variants due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions
  - Low-level somatic variants
  - Single exon deletions/duplications in the following exons:
    - *ABCD4* (NM\_005050) 1; *HCFC1* (NM\_005334) 26; *MTHFR* (NM\_001330358) 1; *PCCB* (NM\_001178014) 4; *SUCLA2* (NM\_003850) 11

## Analytical Sensitivity

For massively parallel sequencing:

Variant Class	Analytical Sensitivity (PPA) Estimate <sup>a</sup> (%)	Analytical Sensitivity (PPA) 95% Credibility Region <sup>a</sup> (%)
SNVs	99.2	96.9-99.4
Deletions 1-10 bp	93.8	84.3-98.2
Deletions 11-44 bp	100	87.8-100
Insertions 1-10 bp	94.8	86.8-98.5
Insertions 11-23 bp	100	62.1-100

<sup>a</sup>Genes included on this test are a subset of a larger methods-based validation from which the PPA values are derived.  
bp, base pairs; PPA, positive percent agreement; SNVs, single nucleotide variants

## Genes Tested

Gene	Alias Symbol(s)	MIM Number	Disorder	Inheritance
<b><i>ABCD4</i></b>	PXMP1L, PMP69, P70R, EST352188	603214	Methylmalonic aciduria and homocystinuria, cblJ type	AR
<b><i>ACSF3</i></b>		614245	Combined malonic and methylmalonic aciduria	AR
<b><i>ADK</i></b>	AK	102750	Hypermethioninemia due to adenosine kinase deficiency	AR

Gene	Alias Symbol(s)	MIM Number	Disorder	Inheritance
<b>AHCY</b>	SAHH	180960	Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency	AR
<b>AMN</b>	amionless	605799	Megaloblastic anemia 1, Norwegian type	AR
<b>CBLIF (GIF)</b>	TCN3, IF, IFMH, INF	609342	Intrinsic factor deficiency	AR
<b>CBS</b>	HIP4	613381	Homocystinuria due to cystathionine beta-synthase deficiency	AR
<b>CD320</b>	8D6, 8D6A	606475	Methylmalonic aciduria, transient, due to transcobalamin receptor defect	AR
<b>CUBN</b>	MGA1, IFCR, gp280	602997	Megaloblastic anemia 1, Finnish type	AR
<b>GNMT</b>		606628	Glycine N-methyltransferase deficiency	AR
<b>HCFC1</b>	HFC1, MRX3, HCF-1, HCF1, CFF, VCAF, MGC70925, PPP1R89	300019	Methylmalonic acidemia and homocysteinemia, cblX type; intellectual disability, X-linked 3	XL
<b>LMBRD1</b>	C6orf209, FLJ11240, bA810I22.1, cblF	612625	Methylmalonic aciduria and homocystinuria, cblF type	AR
<b>MAT1A</b>	MAT, SAMS, MATA1, SAMS1	610550	Methionine adenosyltransferase I/III deficiency	AD and AR
<b>MCEE</b>	GLOD2	608419	Methylmalonyl-CoA epimerase deficiency	AR
<b>MMAA</b>	cblA	607481	Methylmalonic aciduria, B <sub>12</sub> responsive, cblA type	AR
<b>MMAB</b>	cblB, CFAP23	607568	Methylmalonic aciduria, cblB type	AR
<b>MMACHC</b>	DKFZP564I122, cblC	609831	Methylmalonic aciduria and homocystinuria, cblC type	AR
<b>MMADHC</b>	C2orf25, CL25022, cblD	611935	Methylmalonic aciduria and homocystinuria, cblD type	AR
<b>MMUT (MUT)</b>	MCM	609058	Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency, mut (0) type	AR
<b>MTHFR</b>		607093	Homocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate	AR
<b>MTR</b>	cblG	156570	Homocystinuria-megaloblastic anemia, cblG complementation type	AR
<b>MTRR</b>	cblE	602568	Homocystinuria-megaloblastic anemia, cblE complementation type	AR
<b>PCCA</b>		232000	Propionic acidemia	AR
<b>PCCB</b>		232050	Propionic acidemia	AR
<b>SUCLA2</b>		603921	Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria)	AR
<b>SUCLG1</b>		611224	Mitochondrial dna depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria)	AR
<b>TCN1</b>	TCI, TC1	189905	Transcobalamin I deficiency	AR
<b>TCN2</b>	D22S676, D22S750, TC2	613441	Transcobalamin II deficiency	AR

AD, autosomal dominant; AR, autosomal recessive; XL, X-linked

## REFERENCES

Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, Huemer M, Hochuli M, Assoun M, Ballhausen D, Burlina A, Fowler B, Grünert SC, Grünwald S, Honzik T, Merinero B, Pérez-Cerdá C, Scholl-Bürgi S, Skovby F, Wijburg F, MacDonald A, Martinelli D, Sass JO, Valayannopoulos V, Chakrapani A. [Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia](#). Orphanet J Rare Dis. 2014; 9: 130. PubMed

Cusmano-Ozog K, Levine S, Martin M, Packman S, Rosenblatt D, Cederbaum S, Cowan T, Enns G. [Cobalamin C disease identified by newborn screening: the California experience](#). In: Program and abstracts for the SIMD annual meeting. Mol Genet Metab. 2007;227-65. [Accessed: Nov 2018]

Manoli I, Sloan J, Venditti C. [Isolated Methylmalonic Acidemia](#). In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews, University of Washington, 1993-2018. Seattle, WA [Last Revision: Dec 2016; Accessed: Nov 2018]

Martins E, Marcão A, Bandeira A, Fonseca H, Nogueira C, Vilarinho L. [Methionine Adenosyltransferase I/III Deficiency in Portugal: High Frequency of a Dominantly Inherited Form in a Small Area of Douro High Lands](#). JIMD Rep. 2012; 6: 107-12. PubMed

Rosenblatt D, Watkins D. [Methylmalonic acidemia without homocystinuria](#). Orphanet. [Last Update: Mar 2012; Accessed: Nov 2018]

Sacharow S, Picker J, Levy H. [Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency](#). In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews, University of Washington, 1993-2018. Seattle, WA [Last Update: May 2017; Accessed: Nov 2018]

Skovby F, Gaustadnes M, Mudd SH. [A revisit to the natural history of homocystinuria due to cystathionine beta-synthase deficiency](#). Mol Genet Metab. 2010 Jan;99(1):1-3. PubMed

Sloan J, Carrillo N, Adams D, Venditti C. [Disorders of Intracellular Cobalamin Metabolism](#). In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews, University of Washington, 1993-2018. Seattle, WA [Last Update: Sep 2018; Accessed: Nov 2018]

Sloan JL, Johnston JJ, Manoli I, Chandler RJ, Krause C, Carrillo-Carrasco N, Chandrasekaran SD, Sysol JR, O'Brien K, Hauser NS, Sapp JC, Dorward HM, Huizing M; NIH Intramural Sequencing Center Group, Barshop BA, Berry SA, James PM, Champaigne NL, de Lonlay P, Valayannopoulos V, Geschwind MD, Gavrillov DK, Nyhan WL, Biesecker LG, Venditti CP. [Exome sequencing identifies ACSF3 as a cause of combined malonic and methylmalonic aciduria](#). Nat Genet. 2011 Aug 14;43(9):883-6. PubMed

Weisfeld-Adams JD, Morrissey MA, Kirmse BM, Salveson BR, Wasserstein MP, McGuire PJ, Sunny S, Cohen-Pfeffer JL, Yu C, Caggana M, Diaz GA. [Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte](#). Mol Genet Metab. 2010; 99(2): 116-23. PubMed

## RELATED TESTS

[Acylcarnitine Quantitative Profile, Plasma 0040033](#)

Method: Tandem Mass Spectrometry

[Amino Acids Quantitative by LC-MS/MS, Plasma 2009389](#)

Method: Quantitative Liquid Chromatography/Tandem Mass Spectrometry

[Organic Acids, Urine 0098389](#)

Method: Gas Chromatography/Mass Spectrometry

[Vitamin B12 with Reflex to Methylmalonic Acid, Serum \(Vitamin B12 Status\) 0055662](#)

Method: Quantitative Chemiluminescent Immunoassay/Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

[Vitamin B12 and Folate 0070160](#)

Method: Quantitative Chemiluminescent Immunoassay

[Methylmalonic Acid, Serum or Plasma \(Metabolic Disorders\) 2005255](#)

Method: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

[Methylmalonic Acid \(MMA\) Quantitative, Urine 0083918](#)

Method: Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry

[Homocysteine, Total 0099869](#)

Method: Quantitative Enzymatic